Chidozie Ugwumba Sells 4,318 Shares of Clene (NASDAQ:CLNN) Stock

Posted by Joseph Casey on Apr 24th, 2026

Clene Inc. (NASDAQ:CLNN – Get Free Report) major shareholder Chidozie Ugwumba sold 4,318 shares of the firm’s stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average price of $6.12, for a total transaction of $26,426.16. Following the sale, the insider directly owned 358,411 shares in the company, valued at $2,193,475.32. The trade was a 1.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

On Tuesday, April 21st, Chidozie Ugwumba sold 61,345 shares of Clene stock. The stock was sold at an average price of $6.14, for a total transaction of $376,658.30.
On Friday, April 17th, Chidozie Ugwumba sold 25,040 shares of Clene stock. The stock was sold at an average price of $6.43, for a total transaction of $161,007.20.
On Thursday, April 16th, Chidozie Ugwumba sold 7,748 shares of Clene stock. The stock was sold at an average price of $6.40, for a total transaction of $49,587.20.
On Wednesday, April 15th, Chidozie Ugwumba sold 6,374 shares of Clene stock. The stock was sold at an average price of $6.48, for a total transaction of $41,303.52.
On Thursday, April 2nd, Chidozie Ugwumba sold 24,925 shares of Clene stock. The stock was sold at an average price of $4.81, for a total transaction of $119,889.25.
On Wednesday, April 1st, Chidozie Ugwumba sold 4,278 shares of Clene stock. The stock was sold at an average price of $4.97, for a total transaction of $21,261.66.
On Tuesday, February 3rd, Chidozie Ugwumba sold 5,559 shares of Clene stock. The stock was sold at an average price of $4.10, for a total transaction of $22,791.90.
On Monday, February 2nd, Chidozie Ugwumba sold 3,800 shares of Clene stock. The stock was sold at an average price of $4.04, for a total transaction of $15,352.00.
On Friday, January 30th, Chidozie Ugwumba sold 5,686 shares of Clene stock. The stock was sold at an average price of $4.13, for a total transaction of $23,483.18.
On Thursday, January 29th, Chidozie Ugwumba sold 15,284 shares of Clene stock. The stock was sold at an average price of $4.32, for a total transaction of $66,026.88.

Clene Stock Down 6.4%

Shares of CLNN opened at $6.15 on Friday. Clene Inc. has a 52-week low of $2.28 and a 52-week high of $13.50. The firm’s fifty day moving average is $5.53 and its two-hundred day moving average is $6.62. The stock has a market cap of $72.45 million, a PE ratio of -2.37 and a beta of 0.62.

Clene (NASDAQ:CLNN – Get Free Report) last announced its earnings results on Thursday, March 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.14). The business had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.03 million. As a group, research analysts anticipate that Clene Inc. will post -1.99 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on CLNN. Canaccord Genuity Group reiterated a “buy” rating and set a $48.00 price target on shares of Clene in a report on Friday, March 13th. D. Boral Capital reiterated a “buy” rating and set a $23.00 price target on shares of Clene in a report on Thursday, March 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Clene in a report on Friday, January 9th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $34.00.

Read Our Latest Report on Clene

Institutional Trading of Clene

A number of institutional investors and hedge funds have recently bought and sold shares of the business. SymBiosis Capital Partners LLC purchased a new stake in Clene during the fourth quarter worth about $4,523,000. Scoggin Management LP increased its stake in Clene by 75.1% during the third quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock worth $1,506,000 after purchasing an additional 107,250 shares during the period. Ensign Peak Advisors Inc increased its stake in Clene by 668.6% during the fourth quarter. Ensign Peak Advisors Inc now owns 114,361 shares of the company’s stock worth $671,000 after purchasing an additional 99,481 shares during the period. Geode Capital Management LLC increased its stake in Clene by 8.0% during the fourth quarter. Geode Capital Management LLC now owns 82,079 shares of the company’s stock worth $482,000 after purchasing an additional 6,090 shares during the period. Finally, Lunt Capital Management Inc. increased its stake in Clene by 2.5% during the third quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock worth $315,000 after purchasing an additional 1,250 shares during the period. 23.28% of the stock is currently owned by hedge funds and other institutional investors.

About Clene

(Get Free Report)

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).